CompletedNCT01192880
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Costa Mesa and 102 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 625
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, China, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT01192880
- Official title
Show the full official title
A Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period
Get this study by email
Recruitment & locations
CompletedCosta Mesa, United States · Escondido, United States · Granada Hills, United States
88 more locations
- La Jolla, United States
- Oceanside, United States
- San Diego, United States
- Torrance, United States
- Lauderhill, United States
- Miami, United States
- Orange City, United States
- Plantation, United States
- Atlanta, United States
- Indianapolis, United States
- Glen Burnie, United States
- Flowood, United States
- Las Vegas, United States
- Toms River, United States
- Buffalo, United States
- New York, United States
- Rochester, United States
- Durham, United States
- Norristown, United States
- Scranton, United States
- Austin, United States
- Irving, United States
- Salt Lake City, United States
- Kirkland, United States
- Burgas, Bulgaria
- Kazanlak, Bulgaria
- Novi Iskar, Bulgaria
- Pazardzhik, Bulgaria
- Plovdiv, Bulgaria
- Radnevo, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Baoding, China
- Beijing, China
- Changsha, China
- Chengdu, China
- GuangzhouGuangdong, China
- Hangzhou, China
- Kunming, China
- Nanjing, China
- Shanghai, China
- Wuhan, China
- Wuxi, China
- Xi'an, China
- Brno, Czechia
- Liberec, Czechia
- Mělník, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Praha 8 - Bohnice, Czechia
- Sternberk, Czechia
- Bari, Italy
- Naples, Italy
- Brescia, Italy
- Milan, Italy
- Turin, Italy
- Pisa, Italy
- Padova, Italy
- Chiba, Japan
- Funabashi-shi, Japan
- Gunma, Japan
- Hiroshima, Japan
- Hokkaido, Japan
- Kanzaki-gun, Japan
- Kita-ku, Japan
- Kitakyushu-shi, Japan
- Kochi, Japan
- Koshi-shi, Japan
- Kumamoto, Japan
- Kurayoshi-shi, Japan
- Nagoya, Japan
- Omuta-shi, Japan
- Sakaishi, Japan
- Sapporo, Japan
- Sendai, Japan
- Shirakawa-shi, Japan
- Tokyo, Japan
- Toyama, Japan
- Toyoake-shi, Japan
- Yokohama, Japan
- Kemerovo, Russia
- Lipetsk, Russia
- Moscow, Russia
- Saint Petersburg, Russia
- Sartatov, Russia
- Talagi, Russia
- Czechia
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Hoffmann-La Roche.
Did this study involve medication?
Yes. The study involved medication, including Placebo, Bitopertin and Antipsychotics.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia